Future Chinese studies are critical to addressing this issue given the higher EGFR mutation rates in Chinese patients with NSCLC compared with their Western counterparts (approximately 28% in unselected Chinese patients with NSCLC vs. 17% in Western populations) (28, 108, 109). This evidence concerns the gene EGFR and non-small cell lung carcinoma.